Mariko Deguchi Selected Research

Therapeutics

3/2011

Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mariko Deguchi Research Topics

Disease

2	Epilepsy (Aura) 01/2014 - 03/2012
1	Breast Neoplasms (Breast Cancer) 01/2016
1	Intellectual Disability (Idiocy) 01/2014
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2011
1	Coronary Disease (Coronary Heart Disease) 03/2011

Drug/Important Bio-Agent (IBA)

2	Valproic Acid (Depakote)FDA LinkGeneric 01/2014 - 03/2012
2	superoxide dismutase 2IBA 01/2014 - 03/2012
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	valylvaline (Val-Val)IBA 01/2014
1	alanylalanine (Ala-Ala)IBA 01/2014
1	Transaminases (Aminotransferases)IBA 03/2012
1	Clopidogrel (Plavix)FDA Link 12/2011
1	Cytochrome P-450 CYP2C19IBA 03/2011

Therapy/Procedure

1	Therapeutics 03/2011